Mobile

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastat...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-004120-21

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the efficacy and safety of treatment with Allovectin-7® versus treatment with DTIC or TMZ in subjects with recurrent metastatic melanoma.

Critère d'inclusion

  • Recurrent metastatic melanoma

Liens